Viatris (VTRS) Q3 2025 10-Q Quarterly Report
Viatris (VTRS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Viatris Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $3.76B Q3 2025, flat YoY ($3.75B Q3 2024); 9-month revenue $10.60B down 5% YoY ($11.21B 2024)
- • Gross margin decreased to 36% Q3 2025 from 39% Q3 2024; 9-month margin 36% vs 39% YoY due to Indore facility impact
- • Best segment: Greater China up 10% Q3 2025 ($615M vs $562M); worst segment: JANZ down 11% Q3 2025 ($306M vs $344M)
- • Operating cash flow $1.5B for 9 months 2025, down $320M YoY; cash repurchases $418M YTD with $975M cash on hand Sept 30, 2025
- • Management cites $2.94B goodwill impairment Q1 2025, ongoing FDA remediation at Indore plant affecting ~$400M revenue reduction YTD, expects 2026 reinspection
Risk Factors
- • New risk: Potential tariffs up to 15% on brand pharmaceuticals from EU due to new bilateral trade agreements
- • Material update: Increased cost of goods and supply chain disruptions from proposed tariffs on pharmaceutical imports and APIs
- • Regulatory risk: Need for regulatory approval delays adapting manufacturing or suppliers under new trade restrictions
- • Operational risk: Competitors may gain advantage if tariffs disproportionately impact Viatris’ sourcing or supply agreements
- • Financial risk: Tariffs and trade restrictions risk reducing profit margins, potentially making some product lines unsustainable
Viatris Q3 2025 Quarterly FinancialsXBRL
Revenue
$3.7B
▲ +0.3% YoY▲ +5.0% QoQ
Net Income
-$128M
▼ -235.2% YoY▼ -2687.0% QoQ
Net Margin
-3.4%
▼ -596bp YoY▼ -329bp QoQ
Source: XBRL data from Viatris Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Viatris Quarterly Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.